VIVUS Announces Scientific Presentations

MOUNTAIN VIEW, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- VIVUS,Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today announced the following scientific presentations:


SLEEP 2013: 27th Annual Meeting of the Associated Professional Sleep Societies (APSS)
June 1-5, 2013
Baltimore Convention Center, Baltimore, Maryland


Poster Presentation Date: Tuesday, June 4th, 2013 from 4:00-6:00 PM
Session Location: Exhibit Hall E, 100 level, Baltimore Convention Center
Poster Number: 205
Abstract Number: 0867

Presentation Title

The Effects of Once-Daily Phentermine 15 mg and Topiramate Extended-Release 92 mg on Cardiometabolic Endpoints in Obese Patients With Obstructive Sleep Apnea

Authors: David H. Winslow, MDa; Charles H. Bowden, MDb; Karen DiDonato, RN, MSNb; Pamela A. McCullough, PhDa

Affiliations: aKentucky Research Group, Louisville, KY; bVIVUS, Inc., Mountain View, CA


81st Annual Scientific Meeting of the European Atherosclerosis Society Congress (EAS)
June 2-5, 2013
LYON Congress Center, Lyon, France


Poster Presentation Date: Monday, June 3rd and Tuesday, June 4th, 2013 from 12:30-15:00 both days; Session Location: Center of the Exhibition area, Lyon Congress Centre


Poster Number: 430

Presentation Title

Weight Loss–Induced Improvements in Lipids in Overweight/Obese Subjects Treated With Phentermine and Topiramate Extended-Release

Authors: Hermann Toplak, MDa; Samuel Klein, MDb; Wesley W. Day, PhDc

Affiliations: aMedical University of Graz, Graz, Austria; bWashington University School of Medicine, St Louis, Missouri, USA; cVIVUS, Inc., Mountain View, California, USA

About Qsymia

Qsymia® (phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia® (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.

The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.


VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. For more information about the company, please visit

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ending December 31, 2012, as amended by the Form 10-K/A filed on April 30, 2013, and periodic reports filed with the Securities and Exchange Commission.

CONTACT: VIVUS, Inc. Dana B. Shinbaum Corporate Development & Investor Relations Investor Relations: The Trout Group Brian Korb 646-378-2923Source:VIVUS, Inc.